News
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Zacks Investment Research on MSN2d
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...
Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Thursday it has begun discussions with the U.S. government to launch ...
Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...
Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...
Our estimate for direct sales and alliance revenues from Comirnaty is $209.9 million, while that for Paxlovid is $523.4 million. PFE’s Zacks Rank & Other Stocks to Consider Pfizer has a Zacks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback